303 related articles for article (PubMed ID: 24460851)
1. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides.
Fichna J; Sałaga M; Stuart J; Saur D; Sobczak M; Zatorski H; Timmermans JP; Bradshaw HB; Ahn K; Storr MA
Neurogastroenterol Motil; 2014 Apr; 26(4):470-81. PubMed ID: 24460851
[TBL] [Abstract][Full Text] [Related]
2. Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not "higher".
Nasser Y; Bashashati M; Andrews CN
Neurogastroenterol Motil; 2014 Apr; 26(4):447-54. PubMed ID: 24641009
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice.
Bashashati M; Storr MA; Nikas SP; Wood JT; Godlewski G; Liu J; Ho W; Keenan CM; Zhang H; Alapafuja SO; Cravatt BF; Lutz B; Mackie K; Kunos G; Patel KD; Makriyannis A; Davison JS; Sharkey KA
Br J Pharmacol; 2012 Mar; 165(5):1556-71. PubMed ID: 21883147
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
5. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
Booker L; Kinsey SG; Abdullah RA; Blankman JL; Long JZ; Ezzili C; Boger DL; Cravatt BF; Lichtman AH
Br J Pharmacol; 2012 Apr; 165(8):2485-96. PubMed ID: 21506952
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of fatty acid amide hydrolase (FAAH) as a novel therapeutic strategy in the treatment of pain and inflammatory diseases in the gastrointestinal tract.
Sałaga M; Sobczak M; Fichna J
Eur J Pharm Sci; 2014 Feb; 52():173-9. PubMed ID: 24275607
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1.
Palumbo-Zerr K; Horn A; Distler A; Zerr P; Dees C; Beyer C; Selvi E; Cravatt BF; Distler O; Schett G; Distler JH
Ann Rheum Dis; 2012 Dec; 71(12):2051-4. PubMed ID: 22915616
[TBL] [Abstract][Full Text] [Related]
8. Full Fatty Acid Amide Hydrolase Inhibition Combined with Partial Monoacylglycerol Lipase Inhibition: Augmented and Sustained Antinociceptive Effects with Reduced Cannabimimetic Side Effects in Mice.
Ghosh S; Kinsey SG; Liu QS; Hruba L; McMahon LR; Grim TW; Merritt CR; Wise LE; Abdullah RA; Selley DE; Sim-Selley LJ; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2015 Aug; 354(2):111-20. PubMed ID: 25998048
[TBL] [Abstract][Full Text] [Related]
9. Modulation of the endocannabinoid system by the fatty acid amide hydrolase, monoacylglycerol and diacylglycerol lipase inhibitors as an attractive target for secretory diarrhoea therapy.
Wasilewski A; Misicka A; Sacharczuk M; Fichna J
J Physiol Pharmacol; 2017 Aug; 68(4):591-596. PubMed ID: 29151076
[TBL] [Abstract][Full Text] [Related]
10. Novel orally available salvinorin A analog PR-38 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
Sałaga M; Polepally PR; Sobczak M; Grzywacz D; Kamysz W; Sibaev A; Storr M; Do Rego JC; Zjawiony JK; Fichna J
J Pharmacol Exp Ther; 2014 Jul; 350(1):69-78. PubMed ID: 24891526
[TBL] [Abstract][Full Text] [Related]
11. The cannabinoid-1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice.
Fichna J; Sibaev A; Sałaga M; Sobczak M; Storr M
Neurogastroenterol Motil; 2013 Aug; 25(8):e550-9. PubMed ID: 23692073
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
13. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
14. Effect of cannabidiol on sepsis-induced motility disturbances in mice: involvement of CB receptors and fatty acid amide hydrolase.
de Filippis D; Iuvone T; d'amico A; Esposito G; Steardo L; Herman AG; Pelckmans PA; de Winter BY; de Man JG
Neurogastroenterol Motil; 2008 Aug; 20(8):919-27. PubMed ID: 18373655
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid amide hydrolase (FAAH) inhibitor PF-3845 reduces viability, migration and invasiveness of human colon adenocarcinoma Colo-205 cell line: an in vitro study.
Wasilewski A; Krajewska U; Owczarek K; Lewandowska U; Fichna J
Acta Biochim Pol; 2017; 64(3):519-525. PubMed ID: 28850633
[TBL] [Abstract][Full Text] [Related]
16. Targeting fatty acid amide hydrolase and transient receptor potential vanilloid-1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with N-arachidonoyl-serotonin (AA-5-HT).
Bashashati M; Fichna J; Piscitelli F; Capasso R; Izzo AA; Sibaev A; Timmermans JP; Cenac N; Vergnolle N; Di Marzo V; Storr M
Neurogastroenterol Motil; 2017 Dec; 29(12):. PubMed ID: 28695708
[TBL] [Abstract][Full Text] [Related]
17. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome.
Salaga M; Binienda A; Tichkule RB; Thakur GA; Makriyannis A; Storr M; Fichna J
Eur J Pharmacol; 2018 Oct; 836():34-43. PubMed ID: 30121173
[TBL] [Abstract][Full Text] [Related]
18. Assessment of anandamide's pharmacological effects in mice deficient of both fatty acid amide hydrolase and cannabinoid CB1 receptors.
Wise LE; Shelton CC; Cravatt BF; Martin BR; Lichtman AH
Eur J Pharmacol; 2007 Feb; 557(1):44-8. PubMed ID: 17217945
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid amide hydrolase (FAAH) inhibitors exert pharmacological effects, but lack antinociceptive efficacy in rats with neuropathic spinal cord injury pain.
Hama AT; Germano P; Varghese MS; Cravatt BF; Milne GT; Pearson JP; Sagen J
PLoS One; 2014; 9(5):e96396. PubMed ID: 24788435
[TBL] [Abstract][Full Text] [Related]
20. Involvement of Endocannabinoids in Alcohol "Binge" Drinking: Studies of Mice with Human Fatty Acid Amide Hydrolase Genetic Variation and After CB1 Receptor Antagonists.
Zhou Y; Huang T; Lee F; Kreek MJ
Alcohol Clin Exp Res; 2016 Mar; 40(3):467-73. PubMed ID: 26857901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
